QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

COGT

QT75Cogent Biosciences, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
34.54
+0.87+2.58%
OverviewShort InterestFilings
COGTQT75Cogent Biosciences, Inc.·NASDAQ
OverviewShort InterestFilings
34.54+2.58%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-3.04
Insider Own-
Shs Outstand170.87M
Perf Week5.89%
Market Cap5.75BForward P/E-EPS next Y-0.78Insider Trans-6.33%Shs Float-Perf Month10.53%
Enterprise Value5.75BPEG0.24EPS next Q-0.55Inst Own-Short Float-Perf Quarter-0.20%
Income-898062900.00P/S0.00EPS this Y26.15%Inst Trans-Short Ratio-Perf Half Y-13.63%
Sales-P/B3.74EPS next Y65.17%ROA-39.24%Short Interest-Perf YTD-2.76%
Book/sh3.56P/C-EPS next 5Y-ROE-83.29%52W High43.73 -21.02%Perf Year353.28%
Cash/sh5.07P/FCF-EPS past 3/5Y-ROIC-42.77%52W Low6.92 399.13%Perf 3Y-
Dividend Est.-EV/EBITDA-16.41Sales past 3/5Y-Gross Margin0.00%Volatility2.27% 3.11%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM14.23%Oper. Margin0.00%ATR (14)1.38Perf 10Y-
Dividend Ex-Date-Quick Ratio15.14Sales Y/Y TTM-Profit Margin0.00%RSI (14)56.40Recom2.40
Dividend Gr. 3/5Y-Current Ratio15.14EPS Q/Q-1.92%SMA204.29%Beta2.42Target Price49.40
Payout0.00%Debt/Eq0.39Sales Q/Q-SMA50-0.03%Rel Volume2.44Prev Close33.67
Employees205LT Debt/Eq0.39EarningsAug 04SMA20011.11%Avg Volume2.01MPrice34.54
IPO DateMar 29, 2018Option/ShortYes / YesEPS/Sales Surpr.0.00% -Net Debt/EBITDA0.01Volume4,894,928Change2.58%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-01-26ReiteratedStifel Nicolaus$40 → $45
May-06-26ReiteratedH.C. Wainwright$52 → $55
Feb-19-26ReiteratedRobert W. Baird$34 → $35
Feb-18-26ReiteratedPiper SandlerOverweight$52
Jan-07-26ReiteratedUBS$60
Jan-06-26ReiteratedH.C. Wainwright$50 → $52
Dec-08-25ReiteratedJefferiesBuy$45 → $48
Nov-11-25ReiteratedRaymond James$30 → $60
Nov-10-25ReiteratedStifel Nicolaus$16 → $40
Nov-10-25ReiteratedWedbushNeutral$38
Latest News
Jun-14-26
Jun-14-2609:13AM
Cogent Biosciences: A Pre-Commercial Biotech With Commercial-Stage LeverageSeekingAlpha
Jun-13-26
Jun-13-2601:00AM
Cogent Biosciences, Inc. (COGT) Presents at European Hematology Association (EHA) 2026 Congress - SlideshowSeekingAlpha
Jun-12-26
Jun-12-2608:03AM
Cogent Biosciences To Present Preclinical Data From Its Novel JAK2 V617F Mutant-Selective Inhibitor At The 2026 European Hematology Association Congress, June 11-14Benzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue2400
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A3450
Gross Profit-11-50
Selling, General and Administrative Excl. Other136443
Research and Development34270233
Other Operating Expense-24-50
Operating Income-23-333-276
Interest Expense030
Unusual Expense
———
Non-Operating Income (Expense)0-7-20
Net Income Before Taxes-23-329-256
Income Taxes
000
Consolidated Net Income-23-329-256
Net Income From Continuing Operations-23-329-256
Net Income-23-329-256
EPS (Recurring)-3.04-2.55-2.46
EPS (Basic, Before Extraordinaries)-3.04-2.55-2.46
EPS (Diluted)-3.04-2.55-2.46
EBITDA-22-321-252
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio
11.51——
Gross Margin-45.83——
Operating Margin-95.83——
Net Margin-95.83——
Shares Outstanding868104
Market Capitalization2762,415—
Operating Lease Expense
———
Insider Trading Volume
$36.03$32.80$29.57$26.34$23.11● Close Price0.00M60.66M121.31M181.97M242.62MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Fairmount Funds Management LLCDirectorMar 31 '26Sale34.667,000,000242,620,0005,503,418Mar 31 12:00 AM
Fairmount Funds Management LLCDirectorJan 22 '26Sale36.403,500,000127,400,0005,503,418Jan 22 12:00 AM
Kearns EvanChief Legal OfficerDec 26 '25Sale38.7065,0002,515,500109,398Dec 30 12:00 AM
Green John L.Chief Financial OfficerDec 26 '25Sale38.6877,0002,978,360131,834Dec 30 12:00 AM
Sachs JessicaChief Medical OfficerDec 26 '25Sale38.7082,6423,198,245133,938Dec 30 12:00 AM
Robinson John EdwardChief Scientific OfficerDec 26 '25Sale38.7490,0003,486,600140,002Dec 30 12:00 AM
Fairmount Funds Management LLCDirectorJul 10 '25Buy9.002,777,77724,999,9939,003,418Jul 14 12:00 AM
Pinnow ColeChief Commercial OfficerJan 14 '25Buy7.6043,750332,41345,848Jan 15 12:00 AM
Fairmount Funds Management LLCDirectorJun 10 '24Option Exercise0.001,501,5001,5006,225,641Jun 12 12:00 AM
Fairmount Funds Management LLC10% OwnerJun 09 '23Buy12.00800,0009,600,0003,272,124Jun 13 12:00 AM
Fairmount Funds Management LLCdirector:Jun 16 '22Buy8.251,200,0009,900,0002,472,124Jun 21 12:00 AM
Green John L.Chief Financial OfficerApr 26 '21Sale8.8635,626315,6463,841Apr 28 12:00 AM
CAMPANA DARIO10% OwnerMay 12 '20Sale0.4698,20045,5453,095,114Oct 08 12:00 AM
CAMPANA DARIO10% OwnerMay 11 '20Sale0.46100,00045,4963,193,314Oct 08 12:00 AM
CAMPANA DARIO10% OwnerMay 08 '20Sale0.46100,00046,3903,293,314Oct 08 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR